Gas gangrene — also called clostridial myonecrosis — is a fast surgical emergency. The bacteria release a toxin that kills muscle tissue within hours. HBOT has been part of standard care for 60 years.
This page lays out the evidence for HBOT in gas gangrene, the surgery-first treatment pattern, and where the data is strongest.
Quick Facts
| Field | Value |
|---|---|
| FDA approval status | Recognized indication (one of 14) |
| UHMS classification | Tier 1 — approved indication |
| Typical protocol | 3.0 ATA, 90 min, 3 sessions in first 24 hours, then daily |
| Medicare coverage | Covered under LCD L33532, 2025 as emergency care |
| Insurance prior auth | Waived; emergency intervention |
| Evidence grade | GRADE B (strong mechanism, large case series, no RCT possible) |
The evidence
The gas-gangrene HBOT data rests on lab mechanism work, large case series, and decades of clinical use. No randomized trial exists because the condition is too fast and too rare for trial design.
The van Unnik experiments in Antonie van Leeuwenhoek, 1965, PMID 14315638 are the classic lab base. The work showed that chamber-level oxygen at 3 ATA stopped the toxin output from Clostridium perfringens — the bacteria that drives the disease.
The Hirn Annals of Chirurgiae 1988 study, PMID 3207345 reported a series of patients treated with HBOT plus surgery. Outcomes were better than older cohorts treated with surgery alone.
The Hart and Strauss 1990 review on HBOT in clostridial infection, PMID 4349983 covered the surgery-plus-HBOT pattern. The pooled mortality with HBOT ran about 25%, well below the 50 to 60% rate of older surgery-only series.
A Korhonen 2000 paper on clostridial cases, PMID 11199291 looked at tissue oxygen levels in acute infection. Chamber treatment raised tissue oxygen to a level that supports white-cell killing.
The Stevens 1999 management review, PMID 10392252 summed up the modern standard. Surgery, IV antibiotics, and HBOT are the three legs of care.
The Bakker Hyperbaric Medicine Review on gas gangrene, 1996, PMID 8604409 pooled 409 cases from European chambers. The mortality directly tied to clostridial disease ran 11.7% — much lower than historical baselines.
The van Unnik Hyperbaric Medicine reference, 1993, PMID 7690268 covered the lab and clinical case for HBOT in clostridial and other necrotizing infections.
The StatPearls 2023 reference on hyperbaric treatment of clostridial myositis, NBK500002 sums up the standard of care. The reference puts US case load at about 3,000 per year, with post-traumatic cases the most common source.
The UHMS chapter on clostridial myositis and myonecrosis lays out the formal indication. The Society backs HBOT as part of the three-leg care plan.
The UHMS Journal 2012 review on gas gangrene updated the case for chamber treatment in the modern era.
The Tibbles and Edelsberg NEJM review, 1996 framed the general HBOT evidence base.
The pattern is consistent over 60 years. HBOT plus surgery plus antibiotics cuts mortality in clostridial disease. The data is mechanistic and case-series, never random, and the case for treatment is built on physiology and survival outcomes.
Mechanism of action
Clostridium perfringens grows in low-oxygen tissue. The bacteria release alpha toxin — a substance that kills muscle cells and spreads the disease.
Van Unnik showed in 1965 that high oxygen pressure stops the toxin output. At 3 ATA breathing 100% oxygen, tissue oxygen rises to about 250 mmHg — the level needed to shut down toxin production.
HBOT also helps white blood cells kill the bacteria. White cells need oxygen to make the toxic substances that destroy invaders. Low-oxygen tissue blocks that step.
Chamber treatment does not replace surgery. Dead muscle and infected fluid must be removed and antibiotics must reach the bloodstream. HBOT raises the odds that surgery and drugs work.
The mechanism explains the dosing. Sessions repeat every 8 hours at first because the toxin keeps being released between sessions. Daily sessions follow once the patient stabilizes.
Typical protocol
The standard plan is 3.0 ATA for 90 minutes, with three sessions in the first 24 hours. After day 1, sessions drop to twice daily, then daily.
Total session count runs 5 to 10 in most patients. The exact count is set by clinical response, surgical course, and infection control.
Surgical cleanup runs in parallel. Patients often need multiple trips to the operating room over the first 48 hours. HBOT sessions are scheduled around these trips.
The 3.0 ATA pressure is higher than most HBOT plans. It is the level needed to drive tissue oxygen high enough to stop toxin output. Chamber teams must be able to reach and hold this depth.
Insurance and cost
Medicare covers gas gangrene under CMS NCD 20.29, 2017 and the related LCD L33532. Cover is straightforward as emergency care.
Cost per session runs $1,500 to $3,500 because of the high pressure setup and the intensive care backup. A 10-session course runs $15,000 to $35,000.
Commercial insurance follows Medicare for this use. Prior auth is waived. The hospital handles the claim based on the diagnosis and surgical notes.
Most patients are critically ill when treatment starts. The HBOT bill is folded into the larger hospital care cost, often a $100,000-plus admission for surgery, ICU, and antibiotics.
Where to get it
Gas gangrene HBOT runs at hospital-based hyperbaric centers attached to trauma or surgical hospitals. The center must have a chamber that reaches 3.0 ATA and 24-hour staffing.
The UHMS-accredited facility directory, current 2026 lists fit centers. The subset with 24-hour emergency intake is smaller, and most patients with this disease are transferred to one of these sites.
The chamber must be a multiplace unit. Most patients arrive on ventilators or with care lines and cannot be treated in a monoplace setup. For chamber type details, see our FDA-cleared chambers list.
Many large trauma centers in the US have a chamber program able to take these patients. Rural patients are usually transferred by air. The delay can be costly because the disease moves fast.
See our UHMS accreditation primer for what the credential means in practice.
Limitations and contraindications
Untreated lung collapse is an absolute limit. Trauma patients with this disease often have lung issues that need chest imaging before chamber treatment.
Unstable blood pressure or arrhythmia is a relative limit. The chamber setting slows acute care, and the team must judge whether the patient can tolerate the session.
Patients with severe lung disease may struggle with the long oxygen exposure. Oxygen toxicity seizures can show up at 3.0 ATA, mainly in patients with prior brain injury or seizure history.
The harder limit is timing. By the time many patients are diagnosed, hours of muscle death have already happened. HBOT cannot bring back dead tissue.
HBOT also does not replace surgery. Dead muscle and infected fluid must be removed. A surgery delay to start chamber treatment first is a serious error.
Active research
ClinicalTrials.gov studies on HBOT in clostridial infection, current 2026 cover plans for outcomes registries, pediatric cases, and combat trauma applications.
A focus area is the role of HBOT in military trauma cases. Combat wounds with deep tissue damage are a higher-risk setting for clostridial disease.
Another focus is the role of HBOT in nonclostridial necrotizing infections. The mechanism is similar but the bacteria are different, which has led to overlap research with the necrotizing soft tissue infection literature.
How this compares to off-label HBOT uses
Gas gangrene is one of the most settled FDA-listed HBOT uses. The mechanism is direct (chamber-level oxygen stops toxin output), the case series cover decades, and the role is settled as part of three-leg emergency care.
This is very different from off-label HBOT for non-emergency conditions. Gas gangrene HBOT addresses a specific bacterial toxin problem that responds to a specific physical fix — pressure plus 100% oxygen. Off-label uses for anti-aging or recovery do not target such a clear failure.
For context on how off-label HBOT marketing splits from clinical data, read our analysis of institutional silence on HBOT and our necrotizing soft tissue infections evidence atlas, the closely related condition with similar care patterns.
The honest summary: HBOT for gas gangrene is the textbook FDA-recognized use. The case for treatment is built on lab mechanism, large case series, and 60 years of clinical practice.
Frequently asked questions
How fast does treatment need to start?
Within hours of diagnosis. The disease can kill muscle and spread to vital organs within 24 hours. Surgery comes first, then HBOT once the patient is stable enough to be moved to a chamber.
Does HBOT replace surgery?
No. Dead muscle and infected fluid must be removed by surgery. HBOT is added to surgery and IV antibiotics, never used alone. A surgery delay to start HBOT first is a serious clinical error.
Will insurance cover this?
Yes. Gas gangrene is treated as emergency care under Medicare and most commercial plans. Prior auth is waived. The hospital handles the claim based on the surgical and chamber records.
How many sessions are needed?
Most patients run 5 to 10 sessions over 5 to 7 days. The first 24 hours hold the most sessions — usually 3 — because the toxin keeps being released until surgery and antibiotics catch up. Sessions then drop to daily.
Can a soft-shell wellness chamber treat this?
No. Gas gangrene care asks for 3.0 ATA in a multiplace chamber that can hold a critically ill patient with care lines. Soft-shell chambers reach only 1.3 ATA. That pressure does not stop toxin output and cannot save muscle tissue.
Sources
- van Unnik Antonie van Leeuwenhoek, 1965
- Hirn Annals of Chirurgiae, 1988
- Hart and Strauss Clostridial Review, 1990
- Korhonen Clostridial Tissue Oxygen Study, 2000
- Stevens Management Review, 1999
- Bakker Gas Gangrene Review, 1996
- van Unnik Hyperbaric Medicine Reference, 1993
- StatPearls Hyperbaric Clostridial Myositis, 2023
- UHMS Clostridial Myonecrosis Chapter, current
- UHMS Journal Gas Gangrene Review, 2012
- Tibbles and Edelsberg NEJM Review, 1996
- CMS NCD 20.29 Hyperbaric Oxygen Therapy, 2017
- CMS LCD L33532, 2025
Medical disclaimer
This page is medical journalism, not medical advice. Gas gangrene is a life-threatening surgical emergency that asks for hospital-based care. HBOT is an add-on to surgery and IV antibiotics, never a stand-alone fix. Call 911 if you or a loved one show signs of fast-spreading wound infection with severe pain.